The Global Next Generation Sequencing (NGS) Market is on track to reach US$ 34.19 billion by 2030, growing at a remarkable CAGR of 18.16% from 2024 to 2030, according to Renub Research. NGS has transformed the field of genomics by enabling rapid, high-throughput DNA sequencing at a fraction of the time and cost of traditional sequencing methods. With its ability to process large amounts of data in parallel, NGS is a cornerstone technology that is reshaping sectors such as personalized medicine, diagnostics, and agricultural biotechnology.

Request a free sample copy of the report: https://www.renub.com/next-generation-sequencing-market-p.php

Key Factors Driving NGS Market Growth

1. Increased Adoption in Clinical Diagnostics

The growing adoption of NGS in clinical diagnostics is a major driver of market expansion. NGS enables comprehensive genetic analysis that can be used for the diagnosis of various diseases, including cancers, rare genetic disorders, and infectious diseases. As healthcare systems worldwide shift toward precision medicine, the ability to sequence patient genomes and identify mutations that influence disease progression and treatment responses has become essential. NGS is particularly valuable in oncology, where it helps identify genetic mutations in tumors, guide personalized treatment decisions, and monitor treatment efficacy.

2. Technological Advancements in NGS

Technological innovations, such as Sequencing by Synthesis (SBS) and Ion Semiconductor Sequencing, have greatly enhanced the capabilities of NGS platforms. These advancements have led to improvements in accuracy, throughput, and cost-effectiveness, making NGS an increasingly attractive option for both research and clinical applications. As NGS technologies continue to evolve, they offer better scalability and lower error rates, allowing for more detailed and precise genomic analyses.

3. Shift from Traditional Techniques to NGS

NGS is steadily replacing older technologies like microarrays, which have limitations in terms of throughput, accuracy, and scalability. NGS provides superior accuracy, greater data resolution, and the ability to detect a broader range of genetic variations. According to a 2022 report by Elsevier, NGS outperforms microarrays in detecting DNA variations and understanding genetic functions, making it a more reliable and versatile tool for genomic research and diagnostics.

4. Growing Demand for Precision Medicine

As the healthcare industry moves towards personalized medicine, the need for technologies that can analyze and interpret genetic information has grown exponentially. NGS plays a central role in this shift, offering precise, patient-specific data that can guide tailored treatment regimens. For example, identifying mutations in cancer-related genes using NGS can help clinicians choose the most effective targeted therapies for individual patients. This demand for genomic-driven treatments is expected to fuel the growth of the NGS market.

Market Segmentation

The NGS market is segmented into products, applications, technologies, end-users, and regions, each contributing to the growing adoption of next-generation sequencing across different sectors.

1. Products: Reagents & Consumables Lead the Way

Among the key product segments, reagents and consumables hold a substantial share of the NGS market. This is largely due to the repeated use of reagents in NGS workflows, including sample preparation kits, target enrichment kits, and other consumables. The growing utilization of NGS in research and clinical applications, such as cancer research and diagnostic testing, is driving the continuous demand for these products. As pharmaceutical companies and research institutes increasingly adopt NGS technologies, the market for reagents and consumables continues to expand.

2. Applications: Diagnostic Use is Dominant

The diagnostics segment is one of the most critical applications for NGS, contributing significantly to the market’s growth. NGS is used extensively in oncology, genetic screening, prenatal diagnostics, and infectious disease testing. By providing insights into genetic mutations and variations, NGS enables more accurate diagnosis and better-targeted treatments for conditions such as cancer, rare genetic disorders, and infectious diseases. As healthcare systems increasingly prioritize genomic-based diagnostics, the demand for NGS technologies in clinical settings is expected to rise.

• Personalized medicine and genetic screening are expected to become even more significant in the coming years as healthcare shifts towards more individualized treatments.
• Agriculture and animal research also represent growing areas of NGS application, where genomic tools are being used to enhance crop yields, improve livestock health, and develop more resilient agricultural products.

3. Technologies: Sequencing by Synthesis (SBS) Dominates

Among the various NGS technologies, Sequencing by Synthesis (SBS) remains one of the most widely used and established methods. SBS involves the stepwise synthesis of complementary DNA strands, with each step generating data that can be used to determine the sequence of nucleotides in the DNA. SBS technology is favored for its high accuracy, cost-effectiveness, and scalability, making it ideal for large-scale genomic studies, clinical diagnostics, and personalized medicine applications.

Other NGS technologies such as Ion Semiconductor Sequencing, Nanopore Sequencing, and Single-Molecule Read Time Sequencing are also growing in prominence, each offering specific advantages in certain applications. For example, nanopore sequencing offers real-time data collection and the ability to sequence longer DNA fragments, which can be beneficial for specific research purposes.

4. End-Users: Academic and Clinical Research Centers

Academic and clinical research centers are expected to be among the fastest-growing segments in the NGS market. The increasing use of NGS in cancer research, specifically for identifying cancer-associated mutations and understanding tumor heterogeneity, is driving this growth. Additionally, NGS technologies are crucial for exploring new genetic pathways, studying disease mechanisms, and discovering novel biomarkers for diagnostics and therapeutics.

Other end-users in the NGS market include pharmaceutical and biotechnology companies, which use NGS for drug discovery and development, and hospitals and clinics, where NGS is increasingly being integrated into routine diagnostic workflows.

Regional Insights: The U.S. to Maintain Market Leadership

North America: The United States Leads

The United States is expected to maintain its leadership position in the global NGS market, driven by its advanced healthcare infrastructure, strong investment in genomics research, and robust regulatory frameworks. The U.S. market benefits from extensive funding for research and development, particularly in genomics and personalized medicine, and is home to many leading NGS companies such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences. The U.S. also has a highly developed biotechnology industry, which continues to support the widespread adoption of NGS technologies.

One notable development in the U.S. is the FDA approval of innovative NGS-based assays like the PredicineCARE™ cfDNA Assay, used for tumor mutation profiling. This is just one example of how NGS is transforming cancer diagnostics and helping the U.S. remain at the forefront of the global market.

Europe and Asia-Pacific: Growing Adoption

Europe and Asia-Pacific are witnessing rapid advancements in NGS technology and its applications. European countries such as Germany, the UK, and France are increasingly adopting NGS for a range of applications in diagnostics, research, and precision medicine. Similarly, in Asia-Pacific, countries like China, Japan, and India are expanding their genomic research initiatives and increasing their investments in healthcare technologies, further propelling the adoption of NGS systems in both clinical and research settings.

Key Market Players

The global NGS market is highly competitive, with numerous players involved in developing, manufacturing, and commercializing NGS platforms and related products. Some of the leading companies in the NGS market include:

• Illumina: A global leader in NGS technologies, providing systems for sequencing, data analysis, and genomics-based diagnostics.
• Thermo Fisher Scientific: A key player in the NGS market, known for its innovative sequencing platforms and reagents.
• Pacific Biosciences: Offers long-read sequencing technologies that are crucial for analyzing complex genomic regions.
• QIAGEN: A leader in molecular diagnostics and NGS-based testing kits.
• Roche: Provides advanced NGS solutions for clinical and research applications.

 

 

Browse Related Report:

 

Next Generation Sequencing Market: https://www.renub.com/next-generation-sequencing-market-p.php

 

United States Next Generation Sequencing Market: https://www.renub.com/united-states-next-generation-sequencing-market-p.php

 

Cancer Diagnostics Market: https://www.renub.com/cancer-diagnostics-market-p.php

 

 

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)

Email: mailto:[email protected]